Patent intelligence · US
US 11603364
Acyl hydrazone derivative compounds for treating disease
Acyl hydrazone derivative compounds for treating disease
Patent details — US 11603364
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 14, 2023
- Expiration
- Mar 9, 2043
- Applicant
- Alterity Therapeutics Limited
- Claims
- 19
- CPC classes
- A61P, A61P25/00, A61P31/00, A61P35/00
Quick answer
US 11603364 (Acyl hydrazone derivative compounds for treating disease) is held by Alterity Therapeutics Limited. Status: granted. Granted Mar 14, 2023. Expires Mar 9, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Alterity Therapeutics Limited
- Grant date
- Expiration
- Claims
- 19
- CPC classes
- A61P, A61P25/00, A61P31/00, A61P35/00
More from Alterity Therapeutics Limited
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 11603364?
US 11603364 (Acyl hydrazone derivative compounds for treating disease) is held by Alterity Therapeutics Limited. Status: granted. Granted Mar 14, 2023. Expires Mar 9, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11603364?
Alterity Therapeutics Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 4 pharmaceutical patents for this assignee.
When does US 11603364 expire?
Our index shows an expiration date of Mar 9, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.